Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 18 and up

Using CBD to manage pain after shoulder surgery

Official title: Cannabidiol (CBD) As A Pain Adjunct in Orthopedic Surgical Patients: A Randomized Control Trial

Run by The Methodist Hospital Research Institute · NCT06381791 · Data updated 2026-11-12

This study is testing if a CBD medication can help people manage pain better after shoulder surgery compared to a placebo.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment80 (estimated)
SponsorThe Methodist Hospital Research Institute
Academic / other
Locations1 site (Houston, Texas)
StatusRecruiting
StartedMay 24, 2024
Main results expectedDecember 30, 2026
Study endsDecember 30, 2027
Registry record updatedApril 16, 2026
Trial IDNCT06381791 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults undergoing specific orthopedic shoulder surgeries such as total shoulder arthroplasty or rotator cuff repair.

Probably not a fit

Patients with a history of liver disease, substance abuse, or those currently using certain medications may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of Epidiolex (cannabidiol) as an additional pain management option for patients who have undergone orthopedic shoulder surgery. Participants will be randomly assigned to receive either Epidiolex or a placebo alongside their standard pain management regimen. They will track their pain levels and medication use in a diary for two weeks post-surgery, with follow-up calls from researchers to monitor compliance and safety. Bloodwork and surveys will be conducted to assess safety and pain outcomes.

Why it matters

Potential benefit: If successful, this study could provide a new pain management option for patients recovering from shoulder surgery.

How similar studies have gone: While the use of CBD for pain management is gaining interest, this specific approach in the context of orthopedic shoulder surgery is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Above the age of 18 years old
* Undergoing a rotator cuff repair surgery
* Receiving standard anesthesia during surgery
* If a subject is of reproductive potential, they must be on effective contraception one month prior, during treatment, and one month following treatment.

Exclusion Criteria:

* Under the age of 18 years old
* History of revision shoulder arthroplasty
* History of liver disease or impairment
* Are currently taking valproate or clobazam
* Are currently taking a moderate/strong CYP3A4 or CYP2C19 inhibitor
* Are currently taking a strong CYP3A4 or CYP2C19 inducer
* Are currently taking narcotics
* History of substance/alcohol abuse
* Those currently or previously under the care of a pain management specialist
* History of marijuana/cannabidiol (not including topical) regular use within the past 6 months
* Allergy related to cannabidiol
* Allergy related to sesame seeds
* Pregnancy (As part of standard of care, all female participants will be administered a urine pregnancy test prior to surgery. A negative test result is required to participate in the study.)
* If you are taking any medications with known risks for suicidal behavior and ideation
* If you have a diagnosed psychiatric disorder
* If you are untreated for a diagnosed sleeping disorder
* If you are actively breastfeeding
* Patients currently taking central nervous system (CNS) depressants
* Patients currently taking other drugs with known hepatotoxicity
* Vulnerable populations.

Patients taking concomitant medications which are substrate of uridine 5'-diphospho-glucuronosyltransferase 1-9 (UGT1A9), uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7), CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and P-gp will be monitored for potential adverse events based on the Epidiolex® label for the concomitant medication being used.

Where it's running

  • Houston Methodist Hospital
    Houston, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Patrick McCulloch, MD — The Methodist Hospital Research Institute
  • Study coordinator: Haley M Goble, MPH, CRCC
  • Email: hmgoble@houstonmethodist.org
  • Phone: 7134413930

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.